DeGraaf J - Search Results

1

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, Wilkins JT, Thanassoulis G. Sniderman AD, et al. Among authors: degraaf j. J Lipid Res. 2018 Jul;59(7):1266-1275. doi: 10.1194/jlr.R082271. Epub 2018 May 16. J Lipid Res. 2018. PMID: 29769239 Free PMC article. Review.

2

Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein.

Sniderman AD, Tremblay A, De Graaf J, Couture P. Sniderman AD, et al. J Clin Lipidol. 2012 Sep-Oct;6(5):427-33. doi: 10.1016/j.jacl.2012.04.081. Epub 2012 May 1. J Clin Lipidol. 2012. PMID: 23009778

3

The spectrum of type III hyperlipoproteinemia.

Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P. Sniderman AD, et al. J Clin Lipidol. 2018 Nov-Dec;12(6):1383-1389. doi: 10.1016/j.jacl.2018.09.006. Epub 2018 Sep 14. J Clin Lipidol. 2018. PMID: 30318453

4

Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.

Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Glavinovic T, et al. J Am Heart Assoc. 2022 Oct 18;11(20):e025858. doi: 10.1161/JAHA.122.025858. Epub 2022 Oct 10. J Am Heart Assoc. 2022. PMID: 36216435 Free PMC article. Review.

5

A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.

de Graaf J, Couture P, Sniderman A. de Graaf J, et al. Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):608-18. doi: 10.1038/ncpendmet0982. Epub 2008 Oct 7. Nat Clin Pract Endocrinol Metab. 2008. PMID: 18838971 Review.

6

Regulation of plasma LDL: the apoB paradigm.

Sniderman AD, De Graaf J, Couture P, Williams K, Kiss RS, Watts GF. Sniderman AD, et al. Clin Sci (Lond). 2009 Nov 23;118(5):333-9. doi: 10.1042/CS20090402. Print 2010 Mar. Clin Sci (Lond). 2009. PMID: 19922416 Free PMC article.

7

Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Sniderman A, Couture P, de Graaf J. Sniderman A, et al. Nat Rev Endocrinol. 2010 Jun;6(6):335-46. doi: 10.1038/nrendo.2010.50. Epub 2010 Apr 27. Nat Rev Endocrinol. 2010. PMID: 20421882 Review.

8

Non-HDL C equals apolipoprotein B: except when it does not!

Sniderman A, Williams K, de Graaf J. Sniderman A, et al. Curr Opin Lipidol. 2010 Dec;21(6):518-24. doi: 10.1097/MOL.0b013e32833ee80c. Curr Opin Lipidol. 2010. PMID: 20827192 Review.

9

Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study.

Holewijn S, Sniderman AD, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Holewijn S, et al. Eur J Clin Invest. 2011 Apr;41(4):423-33. doi: 10.1111/j.1365-2362.2010.02426.x. Epub 2010 Dec 3. Eur J Clin Invest. 2011. PMID: 21128932

10

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.

Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. Sniderman AD, et al. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. doi: 10.1161/CIRCOUTCOMES.110.959247. Epub 2011 Apr 12. Circ Cardiovasc Qual Outcomes. 2011. PMID: 21487090

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page